Medtronic Targets Airway Management, Respiratory Monitoring For Rapid Growth
Executive Summary
Medtronic is moving quickly to increase its market share in airway management and respiratory monitoring and is expanding its product portfolio to help hospitals reduce the incidence of respiratory compromise and preventable adverse events. The company recently acquired Aircraft Medical and its video laryngoscopy business, launched its own laryngeal mask product and identified a wide range of potential applications for its fast-growing capnography product line.
You may also be interested in...
Market Intel: Medtronic, Philips, Masimo, And Others Keep Pulse Beating In Oximetry Patient Monitoring Market
Demand for reliable, accurate, high-quality pulse oximetry devices in and – increasingly – outside hospitals is driven by the rise of chronic diseases, a growing elderly population prone to asthma, heart disease, sleep apnea and chronic obstructive pulmonary disease, as well as the need to monitor oxygen levels in premature babies. According to a new report by Meddevicetracker, the global market for standalone, hospital-grade pulse oximetry devices and accessories will reach $1.9bn by 2021, a CAGR of 5.4% from 2016. In this feature, we'll take a closer look at the overall pulse oximetry market, the major players and which forces are driving – and stymying – its growth.
Video Tech Boosts Airway Management Market
Innovation in intubation devices, particularly video-enabled technology, is breathing new life into the market for airway management products. At the 2010 meeting of the American Society of Anesthesiologists, held in San Diego in October, manufacturers showcased a variety of new intubation devices designed to improve visualization, avoid complications, and provide fast and simple solutions for patients with difficult airways.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.